改良格拉斯哥预后评分对头颈部鳞状细胞癌的效用:系统综述与荟萃分析
该系统综述与荟萃分析检索EMBASE、PubMed和Cochrane Library至2022年6月30日,纳入11项研究共2017例头颈部鳞状细胞癌患者,评估改良格拉斯哥预后评分(mGPS)与生存结局的关联。随机效应荟萃分析显示,较高的mGPS与较差的无进展生存、总生存、疾病特异性生存和无病生存相关。mGPS可作为头颈部鳞状细胞癌患者的有效预后生物标志物。
要点
- 较高mGPS与较差无进展生存相关(HR=2.39,95%CI 1.69-3.38)。
- 较高mGPS与较差总生存相关(HR=2.40,95%CI 1.94-2.98)。
- 较高mGPS与较差疾病特异性生存和无病生存相关(HR分别为2.57和2.67)。
核心结论
- mGPS可作为诊断为头颈部鳞状细胞癌患者的有效预后生物标志物。
研究设计与样本
- 系统综述与荟萃分析,检索EMBASE、PubMed和Cochrane Library从建库至2022年6月30日,纳入11项研究共2017例头颈部鳞状细胞癌患者。
主要发现
- 较高mGPS与较差无进展生存相关(HR=2.39,95%CI 1.69-3.38)。
- 较高mGPS与较差总生存相关(HR=2.40,95%CI 1.94-2.98)。
- 较高mGPS与较差疾病特异性生存相关(HR=2.57,95%CI 1.71-3.88)。
- 较高mGPS与较差无病生存相关(HR=2.67,95%CI 1.51-4.73,所有p≤0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Whether the modified Glasgow prognostic score (mGPS) is useful for patients with head and neck squamous cell carcinoma (HNSCC) remains controversial. An electronic database search on EMBASE, PubMed, and the Cochrane Library from inception to 30 June 2022 was performed for study selection and data extraction. The associations between the mGPS and survival outcomes were evaluated using a random-effects meta-analysis and expressed as pooled hazard ratios (HRs) and 95% CIs. We included 11 studies involving a total of 2017 patients with HNSCC. A higher mGPS was associated with poorer progression-free survival (HR = 2.39, 95% CI 1.69-3.38), overall survival (HR = 2.40, 95% CI 1.94-2.98), disease-specific survival (HR = 2.57, 95% CI 1.71-3.88), and disease-free survival (HR = 2.67, 95% CI 1.51-4.73, all p ≤ 0.001) in HNSCC. The mGPS can function as a valid prognostic biomarker for patients diagnosed as having HNSCC.
引用
- Luan CW, Kuo LT, Wang YT, et al. Utility of modified Glasgow prognostic score for head and neck squamous cell carcinoma: Systematic review and meta-analysis. Head Neck. 2023. PMID: 37161915. doi:10.1002/hed.27397
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。